Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV. Ellen Maher, Richard Pazdur, Laura L. Fernandes et al.|Journal of Clinical Oncology|2019Cited by 348
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Julia A. Beaver, Chana Weinstock et al.|Clinical Cancer Research|2020Cited by 186
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated TumorsJaleh Fallah, Julia A. Beaver, Laleh Amiri‐Kordestani et al.|Clinical Cancer Research|2022Cited by 180
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i>-Mutated Metastatic Castrate-Resistant Prostate CancerMitchell S. Anscher, Julia A. Beaver, Elaine Chang et al.|The Oncologist|2020Cited by 74
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate CancerMichael H. Brave, Julia A. Beaver, Chana Weinstock et al.|Clinical Cancer Research|2020Cited by 29